Pfizer stock drops after obesity-drug data, even as 2026 outlook holds
Pfizer shares fell 3.3% to $25.79 after its obesity drug trial showed up to 12.3% placebo-adjusted weight loss but about 10% of participants dropped out due to side effects. The company reaffirmed its 2026 outlook, citing policy and patent pressures, and plans to present full VESPER-3 trial data on June 6.